Osphena (Ospemifene) for Women 65 and Older: What to Know About Geriatric Use and Transitioning Care

What Is Ospemifene and Why Does Life Stage Matter So Much at 65+?

Ospemifene is a third-generation SERM that selectively activates estrogen receptors in vaginal and vulvar tissue without stimulating the endometrium at the approved 60 mg dose. For women in their mid-60s and beyond, GSM affects an estimated 27 to 84 percent of postmenopausal women yet remains chronically undertreated, partly because many older women and their clinicians assume vaginal atrophy is simply an inevitable part of aging that does not warrant a prescription.

It is not. GSM worsens progressively the longer estrogen deprivation continues, and women who are 10 or more years past their final menstrual period often have more severe mucosal changes than women in early postmenopause.

Why Turning 65 Changes the Clinical Calculation

Physiological aging introduces several variables that did not apply when ospemifene's phase III trials enrolled their populations, most of whom were in their mid-to-late 50s.

Renal and hepatic clearance. Ospemifene is extensively metabolized by CYP2C9, CYP3A4, and CYP2C19. Age-related decline in hepatic blood flow and CYP enzyme activity can slow ospemifene clearance, potentially raising plasma exposure. The FDA label does not recommend a dose adjustment for age alone, but this pharmacokinetic reality means that any geriatric patient on a CYP2C9 inhibitor (fluconazole, for example) is at higher risk of drug accumulation.

Cardiovascular baseline risk. A woman who is 65 years old carries a statistically higher burden of hypertension, atrial fibrillation, and subclinical atherosclerosis than the average trial participant. Because ospemifene has a class-level signal for VTE and stroke (shared with other SERMs), her absolute risk of a thromboembolic event is meaningfully higher than a 54-year-old's relative risk from the same drug.

Polypharmacy. Women 65 and older fill an average of 4.5 prescription medications simultaneously. Ospemifene interacts with rifampin (potent CYP inducer, lowers ospemifene exposure by roughly 71 percent) and with fluconazole (raises ospemifene AUC by approximately 2.7-fold), making a medication reconciliation review non-negotiable at initiation.

The Understudied Population Problem

The key phase III trials that supported FDA approval enrolled women primarily between ages 40 and 80, but the majority were in their early-to-mid 50s. The Menopause Society notes explicitly that evidence in women older than 75 is limited. If your patient or you are in that older bracket, the prescribing decision requires extrapolating from a younger dataset. That extrapolation is reasonable for efficacy, but the safety extrapolation for cardiovascular risk needs individualized judgment.

How Ospemifene Works in Postmenopausal Vaginal Tissue

Ospemifene binds estrogen receptor alpha and beta with tissue-selective effects. In the vaginal epithelium, it acts as a full agonist, thickening the mucosal layers and shifting the vaginal maturation index toward a pattern that resembles premenopausal tissue. In the endometrium at 60 mg, it behaves as a neutral-to-weak antagonist, which is why no progestogen is needed, a practical advantage for women who cannot tolerate or do not want to add another hormone.

In two randomized controlled trials, ospemifene 60 mg reduced the most bothersome GSM symptom (dyspareunia or dryness) significantly more than placebo at 12 weeks, with improvements maintained at 52 weeks in open-label extensions. The vaginal maturation index score improved by roughly 9 to 13 percentage points in the superficial cell fraction compared with placebo.

For bone, ospemifene shows estrogen-agonist activity in preclinical and early clinical data, but no large randomized trial has established fracture reduction in women 65+. Bone-protective effects, while biologically plausible, should not be the primary justification for prescribing it in older women.

Safety Profile in Women 65 and Older: What the Data Actually Show

Venous Thromboembolism and Stroke

The FDA prescribing information carries a boxed warning about VTE and stroke risk, the same warning borne by other SERMs. In pooled ospemifene clinical trials, the non-fatal stroke rate was 1.45 per 1,000 women-years and the VTE rate was 1.45 per 1,000 women-years, compared with 0.44 and 1.04 per 1,000 women-years for placebo, respectively. These numbers come from populations with a mean age around 59. Older women, particularly those with obesity (BMI <30 used as a reference here; risk rises above it), limited mobility after surgery, or prior VTE, carry a higher absolute risk from these same relative increments.

The Menopause Society's 2023 position statement recommends that clinicians weigh absolute cardiovascular risk before initiating any systemic SERM in postmenopausal women, and that guidance applies squarely to ospemifene in the 65+ age group.

Hot Flashes

Ospemifene acts as a mild estrogen agonist in the hypothalamus, and approximately 7 to 9 percent of women in clinical trials reported new or worsened hot flashes as an adverse effect. For a 65-year-old woman who is a decade past menopause and has already moved through the worst of her vasomotor symptoms, this side effect is less commonly new than it would be for a newly postmenopausal woman. Still, counsel her that hot flashes are possible, particularly in the first 4 to 8 weeks of therapy.

Endometrial Safety at One Year

A 52-week endometrial safety study found no significant difference in endometrial hyperplasia rates between ospemifene 60 mg and placebo. Because ospemifene does not stimulate the endometrium at the approved dose, women without a uterus do not require any progestogen, and women with a uterus also do not, based on current evidence. Annual gynecologic review remains sensible for any woman on a SERM, particularly at 65+, when baseline endometrial pathology rates begin to rise independent of medication.

Cognitive and Fall Risk Considerations

No ospemifene trial has measured fall risk or cognitive outcomes as primary endpoints. This is a genuine evidence gap. Older women who are on sedating medications (opioids, benzodiazepines, anticholinergics) already carry a higher fall risk, and any clinical interaction between these agents and ospemifene has not been studied. The pharmacokinetic concern about CYP2C9 inhibitors noted above applies here again if the patient is on drugs that overlap these pathways.

Pregnancy and Lactation Safety

This section is required for any drug article on WomanRx, even when the indicated population is postmenopausal.

Ospemifene is indicated exclusively in postmenopausal women. It is contraindicated in pregnancy based on animal reproductive toxicology data showing fetal harm at doses lower than the human therapeutic dose. The FDA label classifies ospemifene as causing fetal toxicity in animal studies, and it should never be used in a woman who is pregnant or who might become pregnant.

Women in perimenopause who are still having irregular cycles should confirm they are truly postmenopausal before starting ospemifene. FSH greater than 40 mIU/mL on two measurements 6 weeks apart, or 12 consecutive months of amenorrhea without another cause, are standard benchmarks.

Lactation. Ospemifene transfer into human breast milk has not been studied. Because ospemifene's indicated population is postmenopausal and lactation is physiologically incompatible with true menopause, this is not a clinical scenario that arises in practice. For completeness, animal data show ospemifene is present in rat milk. No prescribing clinician should initiate ospemifene in a breastfeeding woman.

Contraception requirement. No contraception is required in confirmed postmenopausal women (the only approved population). A woman who begins ospemifene before confirmed menopause, for example during late perimenopause with irregular bleeding, should use reliable contraception because of the teratogenicity signal, although this represents an off-label use scenario.

Transitioning Care: What "Transition to Adult Care" Means for Women 65+

The phrase "transition to adult care" in the context of a geriatric patient on ospemifene refers to two common clinical handoffs.

Handoff 1: From OB-GYN to Primary Care or Geriatrics

Many women in their 60s graduate from seeing an OB-GYN annually to seeing an internist or geriatrician as their primary care provider. Ospemifene may have been initiated by the OB-GYN and then inherited by the PCP, who may be less familiar with SERM pharmacology. Key items to communicate in the handoff:

• Current dose (60 mg daily with food, non-negotiable for absorption)
• Most recent pelvic exam or vaginal health assessment
• Whether the patient has a uterus (affects endometrial monitoring decisions)
• Current cardiovascular risk profile and VTE history
• Any CYP2C9 or CYP3A4 interacting medications added since ospemifene was started

The WomanRx Geriatric SERM Transition Checklist (below) consolidates these points into a handoff-ready format that a receiving PCP or geriatrician can act on without needing to re-read the full prescribing information.

WomanRx Geriatric SERM Transition Checklist

| Item | Action at Handoff | |---|---| | Indication confirmed? | GSM: dyspareunia or vaginal dryness documented | | Uterus present? | Yes/No (affects endometrial surveillance plan) | | VTE or stroke history | If yes, ospemifene likely contraindicated; reconsider | | Current cardiovascular risk (Framingham or PCE score) | Document 10-year ASCVD risk | | CYP2C9/CYP3A4 inhibitors or inducers on med list | Reconcile; flag fluconazole, rifampin, ketoconazole | | Mobility and fall risk | Assess; immobility raises VTE risk | | Last pelvic exam date | Schedule if >12 months | | Patient goal for therapy | Symptom relief documented; re-evaluate at 6 months |

Handoff 2: From Academic or Specialty Menopause Center to Community Practice

Women seen at academic menopause centers, where subspecialty menopause practitioners initiate ospemifene, sometimes transition back to community OB-GYNs or PCPs who are less familiar with long-term SERM management. The same checklist applies, with one addition: confirm that the receiving provider understands ospemifene is taken with food (bioavailability increases by approximately 2.5-fold with a high-fat meal compared with fasting, per the FDA label), because a missed counseling point here can produce inconsistent plasma levels and apparent treatment failure.

Who This Is Right For and Who Should Think Twice

Women 65+ Who Are Good Candidates

• Postmenopausal women with confirmed GSM (dyspareunia, vaginal dryness, or both) who want an oral option and cannot tolerate or prefer not to use topical vaginal estrogen
• Women with breast cancer history who are not on aromatase inhibitors, after oncology clearance (note: ospemifene is contraindicated with concurrent tamoxifen and should be approached with caution in estrogen-receptor-positive breast cancer history pending more data)
• Women whose main barrier to vaginal estrogen is applicator difficulty due to arthritis or limited hand dexterity, making an oral tablet a practical alternative
• Women with moderate-to-severe symptoms affecting quality of life where non-hormonal lubricants and moisturizers have not provided sufficient relief, per ACOG's 2022 guidance on GSM management

Women 65+ Who Should Think Carefully or Avoid It

• Women with a personal history of VTE, pulmonary embolism, or stroke (boxed warning contraindication)
• Women with prolonged immobility planned (major orthopedic surgery, for example), where ospemifene should be paused at least 4 to 6 weeks before the procedure, consistent with general SERM guidance
• Women on fluconazole long-term (common in women with recurrent vulvovaginal candidiasis, a real consideration in older women on immunosuppressants) because of the 2.7-fold AUC increase
• Women whose cardiovascular risk on a 10-year ASCVD calculator exceeds 15 to 20 percent, where the absolute VTE and stroke increment from ospemifene may outweigh the benefit for vaginal symptoms alone
• Women older than 75 in whom the evidence base is thinnest and where vaginal estrogen, with its negligible systemic absorption at low doses, may carry a more favorable risk profile

Ospemifene vs. Vaginal Estrogen in Women 65+: A Practical Comparison

The most common clinical question is whether ospemifene or low-dose vaginal estrogen is more appropriate for an older woman. Neither is categorically superior. The choice depends on the woman's preference, comorbidities, and practical factors.

Low-dose vaginal estrogen (estradiol 10 mcg vaginal tablet, estradiol vaginal ring, or conjugated estrogen cream) produces minimal systemic absorption and is generally considered safe even in women with cardiovascular risk factors, based on The Menopause Society's clinical guidance. It requires vaginal application, which some older women find difficult or uncomfortable.

Ospemifene is a once-daily oral tablet. It produces measurable systemic SERM exposure and carries the class-level VTE and stroke boxed warning that vaginal estrogen does not. For a woman with severe GSM and significant applicator difficulty, ospemifene's oral route is a real advantage. For a woman with a history of VTE, vaginal estrogen is substantially safer.

The ACOG Practice Bulletin on GSM states that vaginal estrogen is first-line for isolated vaginal symptoms, with ospemifene as an effective oral alternative. That hierarchy is a starting point, not a rule that overrides individual patient factors.

Monitoring Plan for Women 65+ on Ospemifene

A structured monitoring approach reduces the risk of missed drug interactions, undertreated side effects, and avoidable cardiovascular events.

At initiation:

• Confirm postmenopausal status
• Review full medication list for CYP2C9/CYP3A4 interactors
• Calculate 10-year ASCVD risk (ACC/AHA Pooled Cohort Equations)
• Document baseline vaginal health and most bothersome GSM symptom using a validated scale such as the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire

At 4 to 8 weeks:

• Check for hot flashes (the most common early adverse effect)
• Confirm the patient is taking ospemifene with food
• Ask about any new medications started since initiation

At 3 to 6 months:

• Assess GSM symptom response. If the most bothersome symptom has not improved, reconsider diagnosis or add adjunctive vaginal moisturizer
• Repeat medication reconciliation

At 12 months:

• Pelvic exam if not done in the past year
• Re-evaluate ongoing need. Some women use ospemifene long-term; others achieve sufficient mucosal restoration and can step down to vaginal moisturizers alone

If a new medication is added that inhibits CYP2C9 (fluconazole, amiodarone, metronidazole, miconazole vaginal cream in high doses): discuss the interaction immediately, as ospemifene plasma levels may rise substantially.

The Evidence Gap: What We Do Not Know About Ospemifene in Women Older Than 75

The clinical trial dataset for ospemifene skews younger. A 2023 systematic review of SERM trials confirmed that women older than 75 represent fewer than 8 percent of participants in postmenopausal SERM studies across drug classes, and ospemifene-specific subgroup data for this age bracket have not been published in peer-reviewed literature as of early 2025.

This matters because women older than 75 have fundamentally different pharmacokinetic profiles (lower albumin affecting protein binding, slower hepatic clearance, higher rates of comorbid atrial fibrillation), a higher baseline rate of vaginal atrophy given decades of estrogen deprivation, and fewer competing options if they have contraindications to vaginal estrogen.

The honest clinical position is this: ospemifene is reasonable to consider in a well-selected woman older than 75 with moderate-to-severe GSM, no cardiovascular contraindications, and no significant drug interactions, but the prescribing decision rests on extrapolated rather than directly measured efficacy and safety data in her age bracket. She deserves to know that when you discuss the decision together.

As WomanRx Medical Reviewer Rachel Goldberg, MD, summarizes for clinical practice: "For my patients in their late 60s and 70s with significant vaginal atrophy who struggle with applicators, ospemifene is a real and underused option. The key is doing a proper cardiovascular risk check first and being explicit that we are working with a younger trial population's data when we prescribe it to someone 75 or older."

Practical Prescribing Points at a Glance for 65+ Women

• Dose: 60 mg orally once daily. Always with food. No dose reduction for age alone.
• Duration: No defined maximum duration in the label; reassess benefit-risk annually
• Drug interactions to check first: fluconazole (major CYP2C9 inhibitor), rifampin (major inducer), ketoconazole, and any strong CYP3A4 inhibitor
• Endometrial monitoring: No routine endometrial biopsy required in asymptomatic women based on current evidence, but any unscheduled vaginal bleeding warrants prompt evaluation
• Pelvic floor physical therapy: Complements ospemifene for dyspareunia; refer as needed
• Non-hormonal options to consider alongside: vaginal moisturizers (polycarbophil or hyaluronic acid based) used regularly reduce symptom burden and can be used with ospemifene

If a woman aged 65 or older has confirmed GSM, no VTE or stroke history, a 10-year ASCVD risk below 15 percent, and prefers an oral tablet over a vaginal applicator, ospemifene at 60 mg daily with food is a clinically appropriate choice supported by FDA approval and Menopause Society clinical guidance.